MARKET

IMMP

IMMP

Immutep
NASDAQ
1.840
0.000
0.00%
Closed 19:20 03/25 EDT
OPEN
1.880
PREV CLOSE
1.840
HIGH
1.910
LOW
1.810
VOLUME
72.11K
TURNOVER
0
52 WEEK HIGH
3.335
52 WEEK LOW
1.650
MARKET CAP
267.64M
P/E (TTM)
-8.9932
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IMMP last week (0317-0321)?
Weekly Report · 1d ago
Immutep Announces TACTI-004 Phase III Trial Poster Presentation For Eftilagimod Alfa In Combination With Keytruda And Chemotherapy For 750 Advanced NSCLC Patients Across 150 Sites In 25 Countries At ELCC, March 26-29, 2025
Benzinga · 5d ago
Weekly Report: what happened at IMMP last week (0310-0314)?
Weekly Report · 03/17 10:17
Weekly Report: what happened at IMMP last week (0303-0307)?
Weekly Report · 03/10 10:18
Immutep Ltd (PRRUF) Receives a Buy from Canaccord Genuity
TipRanks · 03/07 02:05
Weekly Report: what happened at IMMP last week (0224-0228)?
Weekly Report · 03/03 10:18
Immutep Reports Increased Revenue Amid Growing R&D Costs
TipRanks · 03/03 03:52
*Immutep Target Price Raised 5.0% to A$2.10/Share by Jefferies>IMM.AU
Dow Jones · 02/26 22:03
More
About IMMP
More
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
Recently
Symbol
Price
%Change

Webull offers Immutep Ltd - ADR stock information, including NASDAQ: IMMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMMP stock methods without spending real money on the virtual paper trading platform.